Combating the TB Pandemic Amid a New Threat
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
A Persistent Shortfall in TB Research and Development Funding
NEW YORK (April 15, 2021)—The 2020 G-Finder Report, released today, shows that low funding levels are putting life-saving science—and especially
Astellas and TB Alliance Enter into a New Collaborative Research Agreement to Identify Lead Compounds for the Treatment of Tuberculosis
TOKYO and NEW YORK (March 31, 2021)—Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and
STAND Clinical Trial Results Published
March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal
TB Alliance Welcomes Drug-Resistant TB Survivors to Access Advisory Committee
NEW YORK (March 24, 2021)—TB Alliance is excited to announce the expansion of its Access Advisory Committee (AAC) to include
Amid Global Pandemic, TB Treatment Innovation Advances at an Unprecedented Pace
PRETORIA (24 March 2021)—On World TB Day, as society reflects on how COVID-19 became the world’s most lethal infection in the
TB Alliance Congratulates MSF on TB-PRACTECAL Milestone
PRETORIA (24 March 2021)—TB Alliance welcomes today’s announcement of the early closing of randomization into the TB-PRACTECAL study. TB-PRACTECAL is a
TB Alliance Issues Call for Researchers to Access TB Biomarker Repository
NEW YORK (March 23, 2021) – Interested researchers are invited to apply to access the MARK-TB (Markedly Accelerating Research with
Marking the Path: Biomarker Research and MARK-TB – An Interview with Riccardo Alagna
Throughout TB Alliance’s history, it has expanded its pursuit and advocacy for various types of TB research, as it identifies
TB Alliance and GSK announce partnership to develop new TB therapeutics
NEW YORK (March 18, 2021)—TB Alliance and GSK have agreed to extend their longstanding collaboration to discover new compounds that